Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients
Elias Bou Samra(Institute for Regenerative Medicine & Biotherapy), Jérôme Moreaux(Centre National de la Recherche Scientifique)
Cited by 20
Related Papers
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
|Clinical Epigenetics|2018|47
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
|Cancers|2019|30
Transient loss of Polycomb components induces an epigenetic cancer fate
|bioRxiv (Cold Spring Harbor Laboratory)|2023|12